- Home
- CRMD
CRMD
CorMedix Inc.
as 07-26-2024 4:00pm EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 279.7M | IPO Year: | 2010 |
| Target Price: | $13.00 | AVG Volume (30 days): | 437.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.57 - $7.00 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 225.63% |
Stock Insider Trading Activity of CorMedix Inc. (CRMD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Todisco Joseph | CRMD | Chief Executive Officer | Mar 13 '24 | Buy | $3.74 | 13,561 | $50,718.14 | 352,839 | SEC Form 4 |
| DUNTON ALAN W | CRMD | Director | Dec 14 '23 | Buy | $3.45 | 3,000 | $10,350.00 | 12,250 | SEC Form 4 |
| DUNTON ALAN W | CRMD | Director | Dec 14 '23 | Buy | $3.30 | 3,000 | $9,900.00 | 15,250 | SEC Form 4 |
Latest CorMedix Inc. News
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
CorMedix Inc. Announces Outpatient Availability of DefenCath
GlobeNewswire
a month ago
CorMedix Inc. Receives FDA Feedback on Potential Label Expansion
GlobeNewswire
2 months ago
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
GlobeNewswire
2 months ago
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
Insider Monkey
2 months ago
CorMedix Inc. (NASDAQ:CRMD) Q1 2024 Earnings Call Transcript
GlobeNewswire
3 months ago
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
GlobeNewswire
3 months ago
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
Compare CRMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.